Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary Non Remunerated Blood Donors (Vnrbd) in Burkina Faso, West Africa

Tao, Issouf; Bisseyé, Cyrille; Nagalo, Bolni Marius; Sanou, Mahamoudou; Kiba, Alice; Surat, Güzin; Compaoré, Tegwindé Rebecca; Traoré, Lassina; Yonli, Albert Théophane; Nikiema, Jean‐Baptiste; Zongo, Jean-Didier; Simporé, Jacques

doi:10.4084/mjhid.2013.053

Cited by 11 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are similar to those reported by Tao et al with a prevalence of 5.4% for EBV among blood donors in Burkina Faso. 32 Our results are also consistent with those reported by Traoré et al . (5.1% and 6.0% respectively for EBV and HHV-6) in blood donors and Ouedraogo et al.…”

Section: Discussionsupporting

confidence: 94%

“…30 , 31 It is currently unknown whether HHV-6 acts simply as an opportunistic pathogen or in synergy with HIV on the disease progression. Some of our previous studies have resulted in the detection of EBV, HHV-6, and CMV among blood donors 32 , 33 and HIV-positive mothers. 34 These studies also made possible to determine the molecular epidemiology of these herpes viruses in the subpopulations concerned by the latter studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ebv and HHV-6 Circulating Subtypes in People Living With Hiv in Burkina Faso, Impact on Cd4 T Cell Count and Hiv Viral Load

Traoré¹,

Nikiema²,

Ouattara³

et al. 2017

Mediterr J Hematol Infect Dis

Self Cite

View full text Add to dashboard Cite

Epstein Barr Virus (EBV) and Human Herpes Virus 6 (HHV-6) are responsible for severe diseases, particularly in immunocompromised persons. There is limited data of the infection of these opportunistic viruses in Burkina Faso.The purpose of this study was to characterize EBV and HHV-6 subtypes and to assess their impact on CD4 T cell count, HIV-1 viral load and antiretroviral treatment in people living with HIV-1. The study population consisted of 238 HIV-positive patients with information on the CD4 T cell count, HIV-1 viral load and HAART. Venous blood samples collected in EDTA tubes were used for EBV and HHV-6 Real Time PCR subtyping.An infection rate of 6.7% (16/238) and 7.1% (17/238) were found respectively for EBV and HHV-6 in the present study. Among EBV infections, similar prevalence was noted for both subtypes (3.9% (9/238) for EBV-1 vs 4.6% (11/238) for EBV-2) with 2.1% (5/238) of co-infection. HHV-6A infection represented 6.3% (15/238) of the study population against 5.0% (12/238) for HHV-6B. EBV-2 infection was significantly higher in patients with CD4 T cell count ≥ 500 compared to those with CD4 T cell count less than 500 cells (1.65% vs 8.56%, p = 0,011). The prevalence of EBV and HHV-6 infections was almost similar in HAART-naive and HAART-experienced patients.The present study provides information on the prevalence of EBV and HHV-6 subtypes in people living with HIV-1 in Burkina Faso. The study also suggests that HAART treatment has no effect on infection with these opportunistic viruses in people living with HIV-1.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Ebv and HHV-6 Circulating Subtypes in People Living With Hiv in Burkina Faso, Impact on Cd4 T Cell Count and Hiv Viral Load

Traoré¹,

Nikiema²,

Ouattara³

et al. 2017

Mediterr J Hematol Infect Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…This prevalence rate is lower than that reported in the general population of Burkina Faso in a previous study (14.5%) (8). It is also lower than the rates reported in blood donors from Nouna, Ouagadougou, and the national blood transfusion center of Burkina Faso (14.3%, 17.3%, and 12.9% respectively) (18,19). However, the prevalence rate reported in the present study is similar to the rates among pregnant women in Burkina Faso (9.3% and 9.8%, respectively) (6, 10).…”

Section: Discussioncontrasting

confidence: 57%

World Hepatitis Day in Burkina Faso, 2016: Awareness, Screening, Identification of HBV Markers, HBV/HCV Coinfection, and Vaccination

et al. 2017

Self Cite

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) can cause chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Coinfection with hepatitis C virus (HCV)/HBV leads to a higher risk of liver damage. Development of HBV awareness campaigns could reduce the prevalence of this disease and limit the consequences. Objectives: The aim of this study was to sensitize, detect, and identify HBV markers and propose vaccination for people not infected with HBV. Methods: With the support of "SOS Hepatitis Burkina" association, an HBV screening program, available for all volunteers, was implemented in several localities of Ouagadougou and the surroundings. A rapid HBsAg detection test was performed on 2207 subjects, who voluntarily answered a series of questions. A rapid detection test of HCV antibodies was performed in HBsAg-positive cases. HBV markers were also determined in HBsAg-positive cases.Results: In a sample of 2207 individuals, aged 1 -85 years (mean age, 31.4 ± 15.7 years), the prevalence of HBsAg was 9.8% (217/2207) after screening. Before screening, 6.8% (150/2207) of the participants claimed that they were vaccinated against HBV. Also, multivariate analysis revealed that HBV infection was significantly associated with age (21 -30 years) and vaccination status (P = 0.03; OR, 1.67; 95% CI, 1.04 to 2.69 and P = 0.003; OR, 5.69; 95% CI, 1.80 to 18.00, respectively). Among 217 HBsAg-positive cases, the prevalence of HBV markers was reported as follows: AbHBs (0.9%), HBeAg (6.0%), AbHBe (87.6%), and AbHBc (100.0%). Based on the findings, HCV was detected in 0.9% (2/217) of HBsAg-positive subjects. In this study, 628 out of 1990 HBsAg-negative subjects were vaccinated for three doses, resulting in a vaccination rate of 31.6%. Conclusions: The present study reported an HBsAg prevalence of 9.8% in the study population. This intervention could contribute to major vaccination coverage against HBV after screening. Therefore, raising awareness and development of screening campaigns on HBV can increase the vaccination coverage of the population. The findings also showed that absence of vaccination against HBV constitutes a high-risk factor for HBV infection.

show abstract

“… 3 , 4 Some prevalences of 14.3%, 17%, and 12.9% has been reported among the blood donors in Nouna, Ouagadougou and the National Blood Transfusion Center of Burkina Faso respectively. 5 , 6 Moreover, prevalences of 9.3% and 9.8% has been reported among pregnant women in Burkina Faso. 7 , 8 …”

Section: Introductionmentioning

confidence: 99%

Occult Hepatitis B Virus Infection and Associated Genotypes Among Hbsag-Negative Subjects in Burkina Faso

Diarra

et al. 2018

Mediterr J Hematol Infect Dis

Self Cite

View full text Add to dashboard Cite

BackgroundThe presence of HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals tested HBsAg negative by currently available assays is defined occult B Infection (OBI). It remains a potential transmission threat and risk to HBV chronic infection. The purpose of this study was to determine the OBI prevalence among HBsAg negative subjects and to characterize associated genotypes.MethodsBlood samples of 219 HBsAg-negative subjects tested by ELISA were collected. HBV DNA was investigated in all samples. Viral loads were determined using quantitative real-time PCR. All samples were screened for HBV markers (anti-HBc, anti-HBe, HBsAg). The Pre-S/S region of the HBV genome was sequenced. The database was analyzed using the SPSS and Epi info software. Phylogenetic analysis was performed using the BioEdit and MEGA software.ResultsOf the 219 samples, 20.1% were anti-HBc positive, 1.8% HBeAg and 22.8% were anti-HBe positive. Fifty-six (56) (25.6%) of the samples had a detectable HBV DNA and viral loads ranging from 4 IU/mL to 13.6 106 IU/mL. Sixteen of them (16/56) had a viral load < 200 IU/mL, resulting in an OBI prevalence of 7.3% (16/219) in our study. The remaining 40 subjects had viral loads > 200 IU/mL, resulting in a “false OBI” prevalence of 18.3% (40/219). HBV genotype E was predominant followed by the quasi-sub-genotype A3. A single “false OBI” strain had the characteristic mutation G145R. Other mutations were observed and all located in the major hydrophilic region (MHR) of the S gene.ConclusionThe study reported a prevalence of 7.3% of occult hepatitis B infection. It confirms the predominance of genotype E and the existence of a subgroup of quasi-sub-genotype A3 of HBV in Burkina Faso. It further provides information on the presence of “false OBI.” This study has found mutations in the major hydrophilic region (MHR) of the pre-S/S gene of HBV.

show abstract

Screening of Hepatitis G and Epstein-Barr Viruses Among Voluntary Non Remunerated Blood Donors (Vnrbd) in Burkina Faso, West Africa

Cited by 11 publications

References 28 publications

Ebv and HHV-6 Circulating Subtypes in People Living With Hiv in Burkina Faso, Impact on Cd4 T Cell Count and Hiv Viral Load

Ebv and HHV-6 Circulating Subtypes in People Living With Hiv in Burkina Faso, Impact on Cd4 T Cell Count and Hiv Viral Load

World Hepatitis Day in Burkina Faso, 2016: Awareness, Screening, Identification of HBV Markers, HBV/HCV Coinfection, and Vaccination

Occult Hepatitis B Virus Infection and Associated Genotypes Among Hbsag-Negative Subjects in Burkina Faso

Contact Info

Product

Resources

About